169 related articles for article (PubMed ID: 37558607)
1. [Targeted systemic treatments and locoregional radiotherapy for breast cancer: Can we expect a benefit from the potentiation of local treatment?].
Camps Maléa A; Hennequin C; Rivera S
Cancer Radiother; 2023 Sep; 27(6-7):535-541. PubMed ID: 37558607
[TBL] [Abstract][Full Text] [Related]
2. [Radiotherapy and targeted therapy for the management of breast cancer: A review].
Beddok A; Cottu P; Fourquet A; Kirova Y
Cancer Radiother; 2023 Sep; 27(5):447-454. PubMed ID: 37173174
[TBL] [Abstract][Full Text] [Related]
3. [New targeted therapies in breast cancer].
Coussy F; Teixeira L; Giacchetti S; Cuvier C; Hocini H; Espié M
Gynecol Obstet Fertil; 2014 Nov; 42(11):787-94. PubMed ID: 25442825
[TBL] [Abstract][Full Text] [Related]
4. A systematic review of dual targeting in HER2-positive breast cancer.
Kümler I; Tuxen MK; Nielsen DL
Cancer Treat Rev; 2014 Mar; 40(2):259-70. PubMed ID: 24080156
[TBL] [Abstract][Full Text] [Related]
5. Combination of radiotherapy and double blockade HER2 with pertuzumab and trastuzumab for HER2-positive metastatic or locally recurrent unresectable and/or metastatic breast cancer: Assessment of early toxicity.
Ajgal Z; de Percin S; Diéras V; Pierga JY; Campana F; Fourquet A; Kirova YM
Cancer Radiother; 2017 Apr; 21(2):114-118. PubMed ID: 28347625
[TBL] [Abstract][Full Text] [Related]
6. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
7. The efficacy of lapatinib in patients with metastatic HER2 positive breast cancer who received prior therapy with monoclonal antibodies and antibody-drug conjugate: a single institutional experience.
Kolarov Bjelobrk I; Radic J; Trifunovic J; Pesic J; Vidovic V; Vranjkovic B; Petrovic N; Andrejic Visnjic B
J Chemother; 2022 Jul; 34(4):264-271. PubMed ID: 34844517
[TBL] [Abstract][Full Text] [Related]
8. Daily Practice Management of pT1a-b pN0 Breast Carcinoma: A Prospective French ODISSEE Cohort Study.
Dalenc F; Penault-Llorca F; Cohen M; Houvenaeghel G; Piat JM; Liegeois P; Puyuelo L; Suchaud JP; Zouai M; Lacroix-Triki M; Radosevic-Robin N; Benkanoun C; Attar-Rabia H; Chauvet MP; Gligorov J; Belkacemi Y
Clin Breast Cancer; 2017 Apr; 17(2):107-116. PubMed ID: 27856201
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic landscape of advanced HER2-positive breast cancer in 2022.
Gupta R; Gupta S; Antonios B; Ghimire B; Jindal V; Deol J; Gaikazian S; Huben M; Anderson J; Stender M; Jaiyesimi I
Med Oncol; 2022 Oct; 39(12):258. PubMed ID: 36224475
[TBL] [Abstract][Full Text] [Related]
10. Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline.
Giordano SH; Temin S; Kirshner JJ; Chandarlapaty S; Crews JR; Davidson NE; Esteva FJ; Gonzalez-Angulo AM; Krop I; Levinson J; Lin NU; Modi S; Patt DA; Perez EA; Perlmutter J; Ramakrishna N; Winer EP;
J Clin Oncol; 2014 Jul; 32(19):2078-99. PubMed ID: 24799465
[TBL] [Abstract][Full Text] [Related]
11. Interaction between Radiation Therapy and Targeted Therapies in HER2-Positive Breast Cancer: Literature Review, Levels of Evidence for Safety and Recommendations for Optimal Treatment Sequence.
Debbi K; Grellier N; Loganadane G; Boukhobza C; Mahé M; Cherif MA; Rida H; Gligorov J; Belkacemi Y
Cancers (Basel); 2023 Apr; 15(8):. PubMed ID: 37190205
[No Abstract] [Full Text] [Related]
12. Intrathecal trastuzumab versus alternate routes of delivery for HER2-targeted therapies in patients with HER2+ breast cancer leptomeningeal metastases.
Lazaratos AM; Maritan SM; Quaiattini A; Darlix A; Ratosa I; Ferraro E; Griguolo G; Guarneri V; Pellerino A; Hofer S; Jacot W; Stemmler HJ; van den Broek MPH; Dobnikar N; Panet F; Lahijanian Z; Morikawa A; Seidman AD; Soffietti R; Panasci L; Petrecca K; Rose AAN; Bouganim N; Dankner M
Breast; 2023 Jun; 69():451-468. PubMed ID: 37156650
[TBL] [Abstract][Full Text] [Related]
13. Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy.
Jeon SH; Shin KH; Kim JH; Kim K; Kim IA; Lee KH; Kim TY; Im SA
Breast Cancer Res Treat; 2018 Dec; 172(3):619-626. PubMed ID: 30209731
[TBL] [Abstract][Full Text] [Related]
14. Controversies of radiotherapy in human epidermal growth factor receptor (HER)-2 positive breast cancer patients.
Kolarova I; Melichar B; Vanasek J; Ryska A; Horackova K; Petera J; Vosmik M; Sirak I; Dolezel M
Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub; 2021 Mar; 165(1):19-25. PubMed ID: 33542544
[TBL] [Abstract][Full Text] [Related]
15. Targeting HER2 in Breast Cancer: Latest Developments on Treatment Sequencing and the Introduction of Biosimilars.
Tesch ME; Gelmon KA
Drugs; 2020 Nov; 80(17):1811-1830. PubMed ID: 33021725
[TBL] [Abstract][Full Text] [Related]
16. [Concurrent radiation therapy and dual HER2 blockade in breast cancer: Assessment of toxicity].
Ben Dhia S; Loap P; Loirat D; Vincent-Salomon A; Cao K; Escalup L; Fourquet A; Kirova Y
Cancer Radiother; 2021 Jul; 25(5):424-431. PubMed ID: 33771453
[TBL] [Abstract][Full Text] [Related]
17. Emerging Therapeutic Options for HER2-Positive Breast Cancer.
Martin M; López-Tarruella S
Am Soc Clin Oncol Educ Book; 2016; 35():e64-70. PubMed ID: 27249772
[TBL] [Abstract][Full Text] [Related]
18. Long-term efficacy and tolerance of a technique for postmastectomy electron beam radiation therapy of the unreconstructed chest wall and lymph node areas for non-metastatic breast cancers.
Souidi S; Loap P; Laki F; Amessis M; Fourquet A; Kirova Y
Cancer Radiother; 2023 Sep; 27(5):362-369. PubMed ID: 37169637
[TBL] [Abstract][Full Text] [Related]
19. Optimal treatment of early stage HER2-positive breast cancer.
Pernas S; Barroso-Sousa R; Tolaney SM
Cancer; 2018 Dec; 124(23):4455-4466. PubMed ID: 30291791
[TBL] [Abstract][Full Text] [Related]
20. Trastuzumab improves locoregional control in HER2-positive breast cancer patients following adjuvant radiotherapy.
Cao L; Cai G; Xu F; Yang ZZ; Yu XL; Ma JL; Zhang Q; Wu J; Guo XM; Chen JY
Medicine (Baltimore); 2016 Aug; 95(32):e4230. PubMed ID: 27512838
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
